May 28 |
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
|
May 28 |
BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment
|
May 24 |
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
|
May 24 |
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
|
May 17 |
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
|
May 15 |
BriaCell falls on $5M stock offering
|
May 15 |
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
|
Apr 24 |
BriaCell Announces Oral and Poster Presentations at ASCO 2024
|
Apr 10 |
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
|
Apr 9 |
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
|